α-synuclein expression in rat substantia nigra suppresses phospholipase D2 toxicity and nigral neurodegeneration

Molecular Therapy

Volumn 18, Issue 10, 2010, Pages 1758-1768

  Gorbatyuk, Oleg S ^a,b   Li, Shoudong ^a,b   Nha Nguyen, Frederic ^a,b   Manfredsson, Fredric P ^a,b   Kondrikova, Galina ^a,b   Sullivan, Layla F ^a,b   Meyers, Craig ^a,b   Chen, Weijun ^a,b   Mandel, Ronald J ^a,b   Muzyczka, Nicholas ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; PHOSPHOLIPASE D2;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; GENE OVEREXPRESSION; IMMUNOCYTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SUBSTANTIA NIGRA; VIRAL GENE THERAPY;

RATTUS;

EID: 77957608019     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.137     Document Type: Article

References (45)

1. Cookson, MR and van der Brug, M (2008). Cell systems and the toxic mechanism(s) of alpha-synuclein. Exp Neurol 209: 5-11.
2. Jenco, JM, Rawlingson, A, Daniels, B and Morris, AJ (1998). Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry 37: 4901-4909.
3. Jenkins, GM and Frohman, MA (2005). Phospholipase D: a lipid centric review. Cell Mol Life Sci 62: 2305-2316.
4. Ahn, BH, Rhim, H, Kim, SY, Sung, YM, Lee, MY, Choi, JY et al. (2002). alpha- Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J Biol Chem 277: 12334-12342.
5. Gorbatyuk, OS, Li, S, Sullivan, LF, Chen, W, Kondrikova, G, Manfredsson, FP et al. (2008). The phosphorylation state of Ser-129 in human {alpha}-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci USA 105: 763-768.
6. Azeredo da Silveira, S, Schneider, BL, Cifuentes-Diaz, C, Sage, D, Abbas-Terki, T, Iwatsubo, T et al. (2009). Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Gen 18: 872-887.
7. Payton, JE, Perrin, RJ, Woods, WS and George, JM (2004). Structural determinants of PLD2 inhibition by alpha-synuclein. J Mol Biol 337: 1001-1009.
8. Oude Weernink, PA, Lopez de Jesus, M and Schmidt, M (2007). Phospholipase D signaling: orchestration by PIP2 and small GTPases. Naunyn Schmiedebergs Arch Pharmacol 374: 399-411
9. Di Fulvio, M, Frondorf, K, Henkels, KM, Lehman, N and Gomez-Cambronero, J (2007). The Grb2/PLD2 interaction is essential for lipase activity, intracellular localization and signaling in response to EGF. J Mol Biol 367: 814-824.
10. Zhao, C, Du, G, Skowronek, K, Frohman, MA and Bar-Sagi, D (2007). Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat Cell Biol 9: 706-712.
11. Iwata, A, Miura, S, Kanazawa, I, Sawada, M and Nukina, N (2001). alpha-Synuclein forms a complex with transcription factor Elk-1. J Neurochem 77: 239-252.
12. Cazzolli, R, Shemon, AN, Fang, MQ and Hughes, WE (2006). Phospholipid signalling through phospholipase D and phosphatidic acid. IUBMB Life 58: 457-461.
13. Lee, CS, Kim, IS, Park, JB, Lee, MN, Lee, HY, Suh, PG et al. (2006). The phox homology domain of phospholipase D activates dynamin GTPase activity and accelerates EGFR endocytosis. Nat Cell Biol 8: 477-484.
14. Burger, C, Gorbatyuk, OS, Velardo, MJ, Peden, CS, Williams, P, Zolotukhin, S et al. (2004). Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 10: 302-317.
15. McFarland, NR, Lee, JS, Hyman, BT and McLean, PJ (2009). Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal system. J Neurochem 109: 838-845.
16. Paterna, JC, Feldon, J and Bueler, H (2004). Transduction profiles of recombinant adeno-associated virus vectors derived from serotypes 2 and 5 in the nigrostriatal system of rats. J Virol 78: 6808-6817.
17. Ulusoy, A, Sahin, G, Bjorklund, T, Aebischer, P and Kirik, D (2009). Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Mol Ther 17: 1574-1584.
18. Peden, CS, Manfredsson, FP, Reimsnider, SK, Poirier, AE, Burger, C, Muzyczka, N et al. (2009). Striatal readministration of rAAV vectors reveals an immune response against AAV2 capsids that can be circumvented. Mol Ther 17: 524-537.
19. Reimsnider, S, Manfredsson, FP, Muzyczka, N and Mandel, RJ (2007). Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 15: 1504-1511.
20. Peng, X, Peng, XM, Tehranian, R, Dietrich, P, Stefanis, L and Perez, RG (2005). Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J Cell Sci 118(Pt 15): 3523-3530.
21. Mandel, RJ, Spratt, SK, Snyder, RO and Leff, SE (1997). Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 94: 14083-14088.
22. Moore, AE, Cicchetti, F, Hennen, J and Isacson, O (2001). Parkinsonian motor deficits are reflected by proportional A9/A10 dopamine neuron degeneration in the rat. Exp Neurol 172: 363-376.
23. Du, G, Huang, P, Liang, BT and Frohman, MA (2004). Phospholipase D2 localizes to the plasma membrane and regulates angiotensin II receptor endocytosis. Mol Biol Cell 15: 1024-1030.
24. Kirik, D, Rosenblad, C, Burger, C, Lundberg, C, Johansen, TE, Muzyczka, N et al. (2002). Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci 22: 2780-2791.
25. Grimm, D, Streetz, KL, Jopling, CL, Storm, TA, Pandey, K, Davis, CR et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541.
26. McBride, JL, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-5873.
27. Lo Bianco, C, Ridet, JL, Schneider, BL, Deglon, N and Aebischer, P (2002). alpha- Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci USA 99: 10813-10818.
28. Chandra, S, Gallardo, G, Fernandez-Chacon, R, Schluter, OM and Sudhof, TC (2005). Alpha-synuclein cooperates with CSPalpha in preventing neurodegeneration. Cell 123: 383-396.
29. Wakamatsu, M, Ishii, A, Ukai, Y, Sakagami, J, Iwata, S, Ono, M et al. (2007). Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. J Neurosci Res 85: 1819-1825.
30. Rappley, I, Gitler, AD, Selvy, PE, LaVoie, MJ, Levy, BD, Brown, HA et al. (2009). Evidence that alpha-synuclein does not inhibit phospholipase D. Biochemistry 48: 1077-1083.
31. Klein, J (2005). Functions and pathophysiological roles of phospholipase D in the brain. J Neurochem 94: 1473-1487.
32. Sciorra, VA, Rudge, SA, Prestwich, GD, Frohman, MA, Engebrecht, J and Morris, AJ (1999). Identification of a phosphoinositide binding motif that mediates activation of mammalian and yeast phospholipase D isoenzymes. EMBO J 18: 5911-5921.
33. Singer, WD, Brown, HA, Jiang, X and Sternweis, PC (1996). Regulation of phospholipase D by protein kinase C is synergistic with ADP-ribosylation factor and independent of protein kinase activity. J Biol Chem 271: 4504-4510.
34. Bhattacharya, M, Babwah, AV, Godin, C, Anborgh, PH, Dale, LB, Poulter, MO et al. (2004). Ral and phospholipase D2-dependent pathway for constitutive metabotropic glutamate receptor endocytosis. J Neurosci 24: 8752-8761.
35. Dhami, GK and Ferguson, SS (2006). Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis. Pharmacol Ther 111: 260-271.
36. Oude Weernink, PA, Han, L, Jakobs, KH and Schmidt, M (2007). Dynamic phospholipid signaling by G protein-coupled receptors. Biochim Biophys Acta 1768: 888-900.
37. Everett, PB and Senogles, SE (2004). D3 dopamine receptor activates phospholipase D through a pertussis toxin-insensitive pathway. Neurosci Lett 371: 34-39.
38. Senogles, SE (2000). The D2s dopamine receptor stimulates phospholipase D activity: a novel signaling pathway for dopamine. Mol Pharmacol 58: 455-462.
39. Senogles, SE (2003). D2s dopamine receptor mediates phospholipase D and antiproliferation. Mol Cell Endocrinol 209: 61-69.
40. Senogles, SE (2007). D2 dopamine receptor-mediated antiproliferation in a small cell lung cancer cell line, NCI-H69. Anticancer Drugs 18: 801-807.
41. Abeliovich, A, Schmitz, Y, Farinas, I, Choi-Lundberg, D, Ho, WH, Castillo, PE et al. (2000). Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron 25: 239-252.
42. Cabin, DE, Shimazu, K, Murphy, D, Cole, NB, Gottschalk, W, McIlwain, KL et al. (2002). Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci 22: 8797-8807.
43. Gorbatyuk, OS, Li, S, Nash, K, Gorbatyuk, M, Lewin, AS, Sullivan, LF et al. (2010). In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther (epub ahead of print).
44. Zolotukhin, S, Byrne, BJ, Mason, E, Zolotukhin, I, Potter, M, Chesnut, K et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973-985.
45. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-167. (Pubitemid 35341079)